Relation
Limitations of Immunogenicity and Safety of a Recombinant ad-5 COVID-19 vaccine
- Limited sample size
- limited participant geographic diversity
- age of participants (no children included in the trial)
- Short time-period to observe effects of the vaccination (only 28 days)
- No possible analysis of risk of ADE because none of the participants were exposed to SARS-CoV-2 post vaccination.
0
1
Updated 2020-10-16
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Methods - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population
Results - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population
Discussion on Immunogenicity and safety of a recombinant ad-5 COVID-19 vaccine
Limitations of Immunogenicity and Safety of a Recombinant ad-5 COVID-19 vaccine